Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors

Biomed Res Int. 2013;2013:102819. doi: 10.1155/2013/102819. Epub 2013 Sep 11.

Abstract

Neuroendocrine tumors (NETs) are tumors originated from neuroendocrine cells in the body. The localization and the detection of the extent of NETs are important for diagnosis and treatment, which should be individualized according to the tumor type, burden, and symptoms. Molecular imaging of NETs with high sensitivity and specificity is achieved by nuclear medicine method using single photon-emitting and positron-emitting radiopharmaceuticals. Somatostatin receptor imaging (SRI) using SPECT or PET as a whole-body imaging technique has become a crucial part of the management of NETs. The radiotherapy with somatostatin analogues labeled with therapeutic beta emitters, such as lutetium-177 or yttrium-90, has been proved to be an option of therapy for patients with unresectable and metastasized NETs. Molecular imaging can deliver an important message to improve the outcome for patients with NETs by earlier diagnosis, better choice of the therapeutic method, and evaluation of the therapeutic response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Lutetium
  • Molecular Imaging*
  • Neuroendocrine Tumors / diagnosis*
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / pathology
  • Positron-Emission Tomography
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Somatostatin / chemistry
  • Receptors, Somatostatin / therapeutic use*
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • Yttrium Radioisotopes

Substances

  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • Somatostatin
  • Lutetium